Neylan John F. 4
4 · KERYX BIOPHARMACEUTICALS INC · Filed Nov 16, 2018
Insider Transaction Report
Form 4
Neylan John F.
Chief Medical Officer
Transactions
- Sale
Common Stock
2018-11-15$2.77/sh−1,156$3,202→ 148,279 total
Footnotes (2)
- [F1]Sale of a total of 1,156 shares of common stock was made in order to satisfy Mr. Neylan's income tax withholding obligation upon the vesting of 4,063 shares of restricted stock on November 14, 2018. Mr. Neylan had no discretion with respect to such sale, which was transacted in accordance with the Issuer's corporate policies regarding the vesting of restricted stock.
- [F2]Includes 66,039 shares of restricted stock.